SYRE
Spyre Therapeutics, Inc. - Common Stock (SYRE)
$25
About Spyre Therapeutics, Inc. - Common Stock (SYRE)
Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product, Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe on December 16, 2013 and is headquartered in Waltham, MA.
Details
Daily high
$93.34
Daily low
$89.85
Price at open
--
52 Week High
$110.18
52 Week Low
$14.50
Market cap
8.0B
Dividend yield
-
Volume
4
Avg. volume
1.4M
P/E ratio
-41.40
Spyre Therapeutics, Inc. - Common Stock News
Details
Daily high
$93.34
Daily low
$89.85
Price at open
--
52 Week High
$110.18
52 Week Low
$14.50
Market cap
8.0B
Dividend yield
-
Volume
4
Avg. volume
1.4M
P/E ratio
-41.40